TRIB
Trinity Biotech plc
There isn't enough reported data to score TRIB yet.
TRIB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Weak |
TRIB's revenue, profitability, cash flow and balance sheet are all currently under pressure.
TRIB PE Valuation
TRIB has no meaningful PE right now: it lost money over the past year.
TRIB Forward outlook
There aren't enough analyst estimates for TRIB to show an outlook.
TRIB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$60.60 | +$21.54 |
| Q3 2025 | -$68.28 | -$0.42 |
| Q2 2025 | -$73.86 | +$6.60 |
| Q1 2025 | -$85.44 | -$2.88 |
| Q4 2024 | -$82.14 | +$14.16 |
| Q3 2024 | -$67.86 | +$46.44 |
| Q2 2024 | -$80.46 | +$42.54 |
| Q1 2024 | -$82.56 | +$113.04 |
TRIB is still losing money, but far less than before: $60.60 per share over the past year, against $195.60 at its worst in early 2023.
TRIB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $11.1M | -30% |
| Q3 2025 | $14.2M | -6% |
| Q2 2025 | $11M | -31% |
| Q1 2025 | $7.6M | -48% |
| Q4 2024 | $15.9M | +18% |
| Q3 2024 | $15.2M | +3.2% |
| Q2 2024 | $15.8M | +14% |
| Q1 2024 | $14.7M | -0.8% |
TRIB's revenue has slid since its 2020 peak: $11M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -27% | +46 points |
| Q3 2025 | -3.8% | +13 points |
| Q2 2025 | -28% | -2.2 points |
| Q1 2025 | -62% | -42 points |
| Q4 2024 | -73% | -47 points |
| Q3 2024 | -17% | +14 points |
| Q2 2024 | -26% | +81 points |
| Q1 2024 | -21% | +5.8 points |
TRIB's operating margin was −27% last quarter, up 46 points from the same quarter a year ago.
TRIB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$1.5M | -351% |
| Q3 2025 | -$77.1K | +$6.2M |
| Q2 2025 | -$1.7M | +$2.6M |
| Q1 2025 | -$3M | +$3.3M |
| Q4 2024 | $615K | +$2.5M |
| Q3 2024 | -$6.3M | -$1M |
| Q2 2024 | -$4.3M | +$715K |
| Q1 2024 | -$6.3M | -$2.9M |
TRIB has burned cash in most quarters: −$6M over the past year, against −$16M the year before.
TRIB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -950 shares |
| 1 year | +31% | +148K shares |
| 3 years | +144% | +367K shares |
| 5 years | +249% | +443K shares |
| Available history | +266% | +451K shares |
TRIB has 620,900 diluted shares, up 31% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $270,000 |
| Q1 2024 | — |
TRIB hasn't bought back shares in the past year.
TRIB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | 12.0x | High |
| Q4 2021 | 7.5x | High |
| Q3 2021 | 16.9x | High |
| Q2 2021 | 5.2x | High |
| Q1 2021 | 11.4x | High |
| Q4 2020 | 24.1x | High |
| Q3 2020 | 3.5x | Elevated |
| Q2 2020 | 6.5x | High |
TRIB's net debt is about 12 years of its operating earnings (EBITDA), up from 11 years a year ago.
TRIB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.6 | Neutral |
| Stochastic | 10.5 | Oversold |
TRIB's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
TRIB PE vs Healthcare Sector
TRIB has no meaningful PE right now: it lost money over the past year.
TRIB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.56 | 10% below |
| 20 week MA | $8.71 | 32% below |
| 50 week MA | $16.5 | 64% below |
TRIB is in a downtrend: it's below all three of its weekly moving averages, and 64% below its 50-week average.
TRIB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $43.8 | $30.0 | -32% |
| 2026 YTD | $30.0 | $5.88 | -80% |
TRIB has finished every year since 2025 lower, and it's down 80% so far in 2026.